trending Market Intelligence /marketintelligence/en/news-insights/trending/q-r-hdrarhfnmqzo5alyuw2 content esgSubNav
In This List

ASCO conference: AstraZeneca blood cancer drug succeeds in phase 3 study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ASCO conference: AstraZeneca blood cancer drug succeeds in phase 3 study

AstraZeneca PLC said the phase 3 trial of moxetumomab pasudotox in a type of blood cancer met its main goal.

About 30% of the 80 patients with hairy cell leukemia, or HCL, that were treated with the drug saw a durable complete response, which means the cancer levels were not detectable in the blood. The patients had not responded to prior treatment, or their cancer had returned after previously being in remission, and they had received at least two prior lines of therapy.

Moxetumomab pasudotox showed a 75% objective response rate, which demonstrates an objective level of change in the presence of the cancer, in the trial known as 1053, the U.K.-based drugmaker said.

In April, the U.S. Food and Drug Administration granted moxetumomab pasudotox priority review status, and it expects to announce its decision on whether to approve the drug in the third quarter.

HCL is a rare cancer of the blood in which an abnormal type of B cell builds up in the blood and bone marrow. About 1,000 individuals in the U.S. are diagnosed with HCL annually. There is no established standard of care for HCL patients and few treatment options are available, the company said.

The 2018 American Society of Clinical Oncology meeting is expected to bring together more than 32,000 professionals from all over the world, with more than 2,500 study abstracts to be presented on site and an additional 3,350 abstracts to be published online.